# InMed 與 Mentari 宣布全股票合併交易，將成立新公司並於納斯達克以新股票代號交易。

*business · news · 2026-05-19 · Seeking Alpha*

## Key points

- InMed Pharmaceuticals 與 Mentari Therapeutics 已同意進行全股票合併交易。
- 合併後的公司將於納斯達克以新股票代號交易。
- 此合併使 InMed Pharmaceuticals 盤前股價上漲約 170%。
- Mentari Therapeutics 專注於開發偏頭痛藥物。

InMed and Mentari announce all-stock merger deal May 19, 2026, 8:51 AM ETInMed Pharmaceuticals Inc. (INM) StockBy : Dulan Lokuwithana, SA News Editor Comments Canadian pharmaceutical company InMed Pharmaceuticals (INM) added ~170% in the premarket on Tuesday after announcing an all-stock merger agreement with migraine drug developer Mentari Therapeutics to create a new entity that will trade on Nasdaq under a new ticker. Waltham, Massachusetts-based Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters

**Companies:** InMed Pharmaceuticals, Mentari Therapeutics
**Countries:** Canada, United States

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4594830-inmed-and-mentari-announce-all-stock-merger-deal)

---

Canonical: https://newsio.io/zh-TW/n/bf5d9946-1005-4cf0-b7b6-b0cefa8b7bde/inmed-mentari-inmed-pharmaceuticals-inm-170
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works